Compare Banco Santander SA (SAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs State Street SPDR S&P Biotech ETF — how do they compare? Banco Santander SA trades at $13.49 (market cap $192.86B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Banco Santander SA is far larger — about 19.1× State Street SPDR S&P Biotech ETF's market cap, and Banco Santander SA pays a 2.06% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SAN | XBI | |
|---|---|---|
Market Cap | $192.86B | $10.11B |
Volume | 10,644,519 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $15.05 | $169.55 |
52-Week Low | $9.65 | $104.99 |
Typical Hold Time | 55 Days | 38 Days |
Enterprise Value | $360.86B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.48, down 1.32% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss. Fundamentals are solid with a 26.25% net income margin and a P/E of 13.55, while cash flow trends have weakened significantly. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence.
The outlook is cautiously optimistic given strong profitability and analyst support, but risks include declining cash flows, high debt levels, and economic sensitivity. The stock's current valuation may appeal to value-oriented investors, though near-term volatility is likely.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
